The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The alliance has focused on the addition of Mallya to Novo Nordisk’s FlexTouch pen injector for insulin delivery ... as well as working towards complete systems that layer in glucose monitoring ...

After moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief ... One way is connecting our delivery systems, such as our pens, to your mobile phone to tell you ...

Hims stock surged above a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. Please watch the video at ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

FREE TO READ] Critics say fragmented ownership, weak culture and a fixation on financial results have harmed innovation ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...